Analyst Research Report Snapshot

Title:

ERYTECH PHARMA - V’ERY HAPPY NEWS YEAR

Price:

$10.00

Provider:

Edison Investment Research

Date:

07 Jan 2014

Pages:

2

Type:

AcrobatPDF

Companies referenced:

ERYP.PA

Available for Immediate Download
Summary:

The next year could be transformational for Erytech, with pivotal data anticipated during Q414 from its unique Graspa product for acute leukaemias. This could lead to first approval in Europe 2016, with partner Recordati well-placed for successful commercialisation. Build-out of the earlier stage pipeline and technologies, in particular Graspa in solid tumours, could provide additional momentum during 2014.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.